Bausch + Lomb shares surged Monday following reports Blackstone and TPG are considering teaming up to buy the eyecare company ...

It was quite a busy and eventful day for the company.

Bausch & Lomb (NYSE:BLCO) jumped 9% in premarket trading on a report that private equity firms TPG (TPG) and Blackstone (BX) ...

The approval comes amidst rumours of a potential private equity buyout of the Canadian company, whose parent company has ...

Bausch Health faces $21 billion in debt, with $10 billion due by 2027 and a $2.4 billion loan due next year. Private equity ...

Fintel reports that on October 15, 2024, Evercore ISI Group upgraded their outlook for Bausch + Lomb (NYSE:BLCO) from In-Line ...

TPG and Blackstone are teaming up to bid for Bausch + Lomb, with an expected valuation between $13 billion and $14 billion.

According to the company, enVista Envy IOLs will be commercially available in the U.S. on a limited basis in the coming weeks ...

In a report released yesterday, Larry Biegelsen from Wells Fargo assigned a Buy rating on Bausch + Lomb Corporation (BLCO – Research ...

Bausch + Lomb Corp. (BLCO, BLCO.TO) announced that the U.S. Food and Drug Administration has approved the enVista Envy full range of ...

Shares in Bausch + Lomb were higher after the company received approval from the Food and Drug Administration for its enVista Envy full range of vision intraocular lens. Shares were recently up 23% at ...

Bausch + Lomb has teamed up with American sportscaster Erin Andrews to promote its dry eye disease treatment, launching the ...